Francine Way

JULY 8, 2017

PE funds typically have 4-to-7-years ownership windows for an investment and look for an exit at the end of that period through a sale or an IPO (initial public offering). PE Portfolio Companies: strategic-financial buyer, typically focus on adding on to current product / service offering, market geography, or customer types.

M&A 130

M&A Acquisitions Sale Investment 130

Mergers and Inquisitions

SEPTEMBER 20, 2023

Firm-Specific and Process Questions – What do you think about our portfolio? So, you could mention a related job, such as strategy, finance, or business development at a portfolio company, and say that you want to return to VC at a higher level eventually. Q: Tell me about the current IPO, M&A, and VC funding markets.

Capital 59

Capital Valuation Investment Portfolio 59

InvestmentBank.com

JANUARY 14, 2021

In September 2020, the National Bureau of Economic Research released a working paper including an industry survey citing 900+ VC firms; this paper revealed a consensus that many portfolio companies were performing quite well in the face of Covid-19 and less than 10% were performing at levels that would raise significant concerns [3] [10].

Capital 40

Capital IPO S&P Hospitality 40

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Mergers and Inquisitions

JULY 31, 2024

The commonalities are that industrial companies serve enterprise customers and governments rather than consumers (with some exceptions, such as airlines) and are very sensitive to broad macro factors and economic conditions. Beyond that, we can say a few things about industrials vs. other verticals within PE.

Private Equity 66

Private Equity Equities Middle Market Debt 66

Mergers and Inquisitions

JANUARY 10, 2024

There is some overlap because at the large banks, wealth management clients often get early/privileged access to investment banking products, such as upcoming IPOs, equity/debt offerings, or new investment products. Note that the scope is more limited in “pure” WM roles; you’ll do more non-portfolio work in private banking.)

Investment Banking 59

Investment Banking Management Bank Banking 59

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

FEBRUARY 1, 2024

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023. Despite some isolated bright spots – such as Thoma Bravo’s $10.7

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59

Cooley M&A

JANUARY 22, 2021

Divestitures, often achieved through asset sales, were also popular in 2020 as large pharmaceutical companies and biotechnology companies sought to divest noncore assets and focus on core businesses in the wake of economic uncertainty created by the pandemic. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

approved prescription cannabidiol medicine to its portfolio. The prevalence of structured acquisitions, however, may be limiting the development of such shelved drugs because the economics of the milestones specified in the merger agreement may not be warranted by the risk?adjusted driven assets. time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

NOVEMBER 18, 2024

Public Markets: It is possible that a few of the car wash platforms with strong growth and financial performance pursue an initial public offering (IPO). A strong car wash IPO could potentially overcome the investor skepticism created by Mister Car Wash and Driven Brands and open the door for a few other platforms to follow suit.

Private Equity 52

Private Equity Equities IPO Valuation 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Mergers and Inquisitions

NOVEMBER 20, 2024

To add a growth equity spin, you can talk about wanting to understand operations and unit economics to evaluate companies. A: You like industries such as tech and healthcare, you like to understand markets, unit economics, and operations, and you want to invest in high-growth companies that need capital. Q: Why growth equity?

Private Equity 59

Private Equity Equities Capital Valuation 59

Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products. The activism specter persists Life sciences companies continue to find themselves in activists crosshairs.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64